Latest news with #VinitJindal
Economic Times
27-05-2025
- Business
- Economic Times
Bayer CropScience shares soar 13% as Q4 profit jumps 49% YoY; board declares Rs 35 dividend
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Bayer CropScience zoomed 13% to an intraday high of Rs 5,792 on the BSE on Tuesday after strong financial performance in Q4. The company reported a 49% YoY jump in its PAT for Q4FY25 at Rs 143.30 crore, while also announcing a dividend of Rs 35 per net profit for the corresponding quarter of the previous financial year stood at Rs 96 the company's board has recommended a dividend of Rs 35 per share for eligible shareholders. The details regarding the record and payout date for the same have not yet been provided by the company registered its revenue from operations for the quarter under review at Rs 1,046.4 crore, up from Rs 792.3 crore in the year-ago FY 2024-25, Bayer CropScience's revenue from operations increased to Rs 5473.4 crore, compared to Rs 5106.2 crore in the previous year."Our Revenue from Operations grew by 7% for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayer's reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs,' said Vinit Jindal, Executive Director and Chief Financial Officer of Bayer CropScience, while commenting on the Q4 is a global enterprise with core competencies in the life science fields of health care and nutrition. It is engaged in the Agri Care business, which primarily includes the manufacture, sale and distribution of insecticides, fungicides, herbicides and various other agrochemical products and corn seeds.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
27-05-2025
- Business
- Time of India
Bayer CropScience shares soar 13% as Q4 profit jumps 49% YoY; board declares Rs 35 dividend
Shares of Bayer CropScience zoomed 13% to an intraday high of Rs 5,792 on the BSE on Tuesday after strong financial performance in Q4. The company reported a 49% YoY jump in its PAT for Q4FY25 at Rs 143.30 crore, while also announcing a dividend of Rs 35 per share. The net profit for the corresponding quarter of the previous financial year stood at Rs 96 crore. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Soacha: Deja que la IA guíe tu trading con CFD y aumenta tus ingresos extra. Trade AI Registrarse Undo Further, the company's board has recommended a dividend of Rs 35 per share for eligible shareholders. The details regarding the record and payout date for the same have not yet been provided by the company. The company registered its revenue from operations for the quarter under review at Rs 1,046.4 crore, up from Rs 792.3 crore in the year-ago period. For FY 2024-25, Bayer CropScience's revenue from operations increased to Rs 5473.4 crore, compared to Rs 5106.2 crore in the previous year. Live Events "Our Revenue from Operations grew by 7% for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayer's reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs,' said Vinit Jindal, Executive Director and Chief Financial Officer of Bayer CropScience, while commenting on the Q4 results. Also read: Olectra Greentech shares tank 13% as Maha gov reportedly cancels big e-bus order Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. It is engaged in the Agri Care business, which primarily includes the manufacture, sale and distribution of insecticides, fungicides, herbicides and various other agrochemical products and corn seeds.
Business Standard
27-05-2025
- Business
- Business Standard
Bayer CropScience spurts after Q4 PAT rises 49% YoY
Bayer CropScience surged 11.58% to Rs 5724 after the company's standalone net profit jumped 49.27% to Rs 143.30 crore while net sales rose 32.07% to Rs 1,046.40 crore in Q4 March 2025 over Q4 March 2024. Profit before tax (PBT) stood at Rs 167.90 crore in Q4 FY25, up 399.70% quarter-on-quarter, and 59.30% year-on-year. However, the company's standalone net profit surged 319.01% while net sales declined 1.04% in Q4 March 2025 over Q3 December 2024. For the full year, net profit fell 23.30% to Rs 568 crore while net sales rose 7.19% to Rs 5,473.40 crore in the year ended March 2025 over the year ended March 2024. PBT declined 24.86% year-on-year to Rs 707.40 crore in FY25 over FY24. The company's standalone net cash from operating activities stood at Rs 262 crore in FY25, lower than Rs 951.60 crore in FY24. Commenting on the quarterly results, Simon Wiebusch, vice chairman, managing director and CEO, Bayer CropScience said, "In Q4, our revenue from Operations grew by 32 percent over the previous year, driven by strong performance in spring corn and by both strong performance and double-digit liquidation growth in the crop protection portfolio. The promotional investments made in the previous quarter generated significant returns. Quarter-on-quarter deviations reflect the realities of our agriculture. Our focus on liquidation-led channel management aligns with market realities and demonstrates our commitment to delivering continuous value." Speaking on the FY results, Vinit Jindal, executive director and chief financial officer, Bayer CropScience, said, "Our Revenue from Operations grew by 7% for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayers reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs." The board has recommended a final dividend payment of Rs 35 per equity share for the financial year ended March 31, 2025, subject to shareholders approval. Bayer CropScience is engaged in 'agri care' business which primarily includes manufacture, sale and distribution of insecticides, fungicides, herbicide and various other agrochemical products.
&w=3840&q=100)
Business Standard
27-05-2025
- Business
- Business Standard
What sparked 13% rally in Bayer CropScience shares today? Find out here
Bayer CropScience share price: Chemical manufacturing company Bayer CropScience shares were in demand on Tuesday, May 27, 2025, with the scrip rising up to 12.90 per cent to an intraday high of ₹5,792. At 10:04 AM, Bayer CropScience share price was up 11.28 per cent at ₹57,08.45. By comparison, BSE Sensex was trading 1.02 per cent lower at 81,341.18 level. Why did Bayer CropScience share price rise in trade today? Bayer CropScience shares gained following the release of strong financial results for the March quarter of FY25 (Q4FY25). In Q4FY25, the company reported revenue from operations of ₹1,046.4 crore, up from ₹792.3 crore in the same quarter last year (Q4FY24). Profit Before Tax rose to ₹167.9 crore in Q4FY25, compared to ₹105.4 crore a year ago. Simon Wiebusch, vice chairman, managing director and CEO, Bayer CropScience said, 'In Q4, our Revenue from Operations grew by 32 per cent over the previous year, driven by strong performance in spring corn and by both strong performance and double-digit liquidation growth in the crop protection portfolio. The promotional investments made in the previous quarter generated significant returns. Quarter-on-quarter deviations reflect the realities of our agriculture. Our focus on liquidation-led channel management aligns with market realities and demonstrates our commitment to delivering continuous value.' For the full fiscal year FY 2024-25 (FY25), revenue from operations increased to ₹5,473.4 crore from ₹5,106.2 crore a year agor. However, Profit Before Tax declined to ₹707.4 crore, down from ₹941.4 crore in the previous fiscal. "Our Revenue from Operations grew by 7 percent for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayer's reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs, said Vinit Jindal, executive director and chief financial officer, Bayer CropScience. Bayer CropScience dividend The Board of Directors has recommended a final dividend payment of ₹35 per equity share of ₹10 each for FY25, subject to shareholders' approval. About Bayer CropScience Bayer is a global life sciences company with core competencies in healthcare and nutrition, dedicated to developing innovative solutions that enhance quality of life and promote environmental sustainability. Its agricultural division, Bayer CropScience, focuses on crop protection, seeds, and digital farming technologies to support farmers in increasing productivity and managing pests and diseases effectively. The division offers a broad portfolio of products including herbicides, pesticides, fungicides, and high-performance seeds, while also advancing sustainable farming practices through ongoing investment in research and development. In fiscal 2024, Bayer employed around 93,000 people, generated €46.6 billion in sales, and invested €6.2 billion in R&D globally.
